Completed OBSERVATIONAL NCT00697658

INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia

INVega Is Studied In an Observational Design in the Netherlands

Sponsor: Janssen-Cilag B.V.

Updated 7 times since 2017 Last updated: Apr 24, 2014 Started: Mar 31, 2008 Primary completion: Nov 30, 2009 Completion: Nov 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00697658, this observational or N/A phase trial focuses on Schizophrenia and remains completed. Sponsored by Janssen-Cilag B.V., it has been updated 7 times since 2008, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: PHASE4 → None
Jan 2017 — Apr 2018 [monthly]

Completed PHASE4

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen-Cilag B.V.

Data source: Janssen-Cilag B.V.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alphen aan den Rijn, Netherlands , Amersfoort, Netherlands , Amsterdam, Netherlands , Beverwijk, Netherlands , Deventer, Netherlands , Echt, Netherlands , Enschede, Netherlands , Geldrop, Netherlands , Heerde, Netherlands , Heerenveen, Netherlands and 7 more locations